Abstract
Despite a regulatory delay in the requirement that US payers publicly post negotiated prices for prescription drugs, some payers have chosen to make this information available. The objective of this study was to assess the availability and utility of net pharmaceutical pricing data posted by commercial payers in response to the CMS Transparency in Coverage rule.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
